Sign in →

Browse by Name

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #
 

Mayo Clinic Laboratories

Test Code 1HIV / 34949-Q HIV-1 GENOTYPING

Additional Codes

Software Test Code
SoftID                                                  1HIV                                                                   
EPIC LAB20158
Quest Diagnostics 34949-Q

Performing Laboratory

Quest Diagnostics

Method Name

DNA Sequencing, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)

Reference Values

An interpretive report will be issued

Report Available

5-10 Days

Specimen Type

Submit one of the following:

~ Cerebrospinal Fluid (CSF)

~ Plasma

Preferred Container

Lavender Top Tube (EDTA) – EDTA plasma

Sterile Container – Container should be leakproof

Preferred Volume

Cerebrospinal Fluid (CSF): 2 mL (Sterile Container)

Plasma: 2 mL (Lavender Top Tube (EDTA))

Minimum Volume

Cerebrospinal Fluid (CSF): 0.6 mL (Sterile Container)

Plasma: 0.6 mL (Lavender Top Tube (EDTA))

Specimen Collection and Handling

Submit one of the following:

BLOOD: Separate plasma from cells within 24 hours of collection by centrifugation. Transfer to a standard aliquot tube with a screw top cap. Ship frozen.

CSF: Transfer to a standard aliquot tube with a screw top cap. Ship frozen.

Specimen Stability Information

Specimen Type: Cerebrospinal Fluid (CSF)

Frozen: 42 Days

Refrigerated: 6 Days

Room Temp: 24 Hours

Must be spun/separated within: 24 Hours

Specimen Type: Plasma

Frozen: 42 Days

Refrigerated: 6 Days

Room Temp: 24 Hours

Must be spun/separated within: 24 Hours

Add On Capable

Yes

Advance Beneficiary Notice Requirements

No ABN Required

CPT Code Information

CPT Code

CPT Description

CPT Disclaimer

87900 Infectious Agent Drug Susceptibility Phenotype Prediction Using Regularly Updated Genotypic Bioinformatics  
87901 Infectious Agent Drug Susceptibility Phenotype Prediction Using Regularly Updated Genotypic Bioinformatics, HIV-1, Reverse Transcriptase and Protease Regions  

Performing Laboratory Location

Quest Diagnostics

LOINC Code Information

48558-1

Clinical Significance

This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients. The test identifies drug resistance-associated mutations in the HIV-1 protease and reverse transcriptase genes. It can be used to predict antiretroviral drug resistance before initiation of therapy and in patients experiencing virologic failure while on therapy.

LIMITATIONS:

An infection is often composed of a variety of strains of the virus. The test may identify only the predominant type of virus thus leaving the minority viruses to thrive once the predominant type is treated. Lack of resistance may not confer susceptibilities.

Rejection Information

Plasma received frozen in the plasma preparation tube (PPT); Serum sample; Whole blood >24 hours old; Frozen whole blood